Sign in or Register   Sign in or Register
  |  

Mouse Anti-NADSYN1 Recombinant Antibody (4G9) (CBMAB-N1063-WJ)

This product is a Mouse antibody that recognizes NADSYN1. The antibody 4G9 can be used for immunoassay techniques such as: ELISA, WB.
See all NADSYN1 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
4G9
Antibody Isotype
IgG1, κ
Application
ELISA, WB

Basic Information

Specificity
Human
Antibody Isotype
IgG1, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.2
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
NAD synthetase 1
Introduction
Nicotinamide adenine dinucleotide (NAD) is a coenzyme in metabolic redox reactions, a precursor for several cell signaling molecules, and a substrate for protein posttranslational modifications. NAD synthetase (EC 6.3.5.1) catalyzes the final step in the biosynthesis of NAD from nicotinic acid adenine dinucleotide (NaAD).[supplied by OMIM, Apr 2004]
Entrez Gene ID
55191
UniProt ID
Q6IA69
Alternative Names
NAD Synthetase 1; NAD(+) Synthase [Glutamine-Hydrolyzing]; NAD(+) Synthetase; EC 6.3.5.1;
Function
Catalyzes the final step of the nicotinamide adenine dinucleotide (NAD) de novo synthesis pathway, the ATP-dependent amidation of deamido-NAD using L-glutamine as a nitrogen source.
Biological Process
de novo' NAD biosynthetic process Source: UniProtKB
NAD biosynthetic process Source: GO_Central
Cellular Location
Cytosol
Other locations
cytoplasm
Involvement in disease
Vertebral, cardiac, renal, and limb defects syndrome 3 (VCRL3):
An autosomal recessive, lethal disorder characterized by severe cardiac and renal anomalies, including hypoplastic or absent left ventricle, transposition of the great arteries, absent pulmonary trunk, and hypoplastic or absent kidneys. Patients also exhibit vertebral segmentation defects and shortening of the proximal long bones or micromelia. Death occurs in early infancy.

Jiang, L. J., Guo, S. B., Zhou, Z. H., Li, Z. Y., Zhou, F. J., Yu, C. P., ... & Tian, X. P. (2024). Snai2‐mediated upregulation of NADSYN1 promotes bladder cancer progression by interacting with PHB. Clinical and Translational Medicine, 14(1).

Erbs, E., Brasen, C. L., Lund, A. M., & Rasmussen, M. (2023). Adult patient diagnosed with NADSYN1 associated congenital NAD deficiency and analysis of NAD levels to be published in: European Journal of Medical Genetics. European Journal of Medical Genetics, 66(3), 104698.

Meijer, N. W., Gerrits, J., Zwakenberg, S., Zwartkruis, F. J., Verhoeven-Duif, N. M., & Jans, J. J. (2023). Metabolic Alterations in NADSYN1-Deficient Cells. Metabolites, 13(12), 1196.

Aubert‐Mucca, M., Janel, C., Porquet‐Bordes, V., Patat, O., Touraine, R., Edouard, T., ... & Baujat, G. (2023). Clinical heterogeneity of NADSYN1‐associated VCRL syndrome. Clinical Genetics, 104(1), 114-120.

Kortbawi, H., Ames, E., Pritchard, A., Devine, P., van Ziffle, J., & Slavotinek, A. (2022). Further description of two patients with biallelic variants in NADSYN1 in association with cardiac and vertebral anomalies. American Journal of Medical Genetics Part A, 188(8), 2479-2484.

Alaylıoğlu, M., Dursun, E., Genc, G., Şengül, B., Bilgiç, B., Gündüz, A., ... & Gezen-Ak, D. (2022). Genetic variants of vitamin D metabolism-related DHCR7/NADSYN1 locus and CYP2R1 gene are associated with clinical features of Parkinson’s disease. International Journal of Neuroscience, 132(5), 439-449.

Ząbek, T., Witarski, W., Semik-Gurgul, E., Szmatoła, T., Kowalska, K., & Samiec, M. (2022). Differential expression and methylation patterns of NFATC1, NADSYN1 and JAK3 gene in equine chondrocytes expanded in monolayer culture. Research in Veterinary Science, 152, 48-52.

Lin, J., Zhao, L., Zhao, S., Li, S., Zhao, Z., Chen, Z., ... & Wu, N. (2021). Disruptive NADSYN1 variants implicated in congenital vertebral malformations. Genes, 12(10), 1615.

Szot, J. O., Campagnolo, C., Cao, Y., Iyer, K. R., Cuny, H., Drysdale, T., ... & Dunwoodie, S. L. (2020). Bi-allelic mutations in NADSYN1 cause multiple organ defects and expand the genotypic spectrum of congenital NAD deficiency disorders. The American Journal of Human Genetics, 106(1), 129-136.

Jones, P., Lucock, M., Chaplin, G., Jablonski, N. G., Veysey, M., Scarlett, C., & Beckett, E. (2020). Distribution of variants in multiple vitamin D-related loci (DHCR7/NADSYN1, GC, CYP2R1, CYP11A1, CYP24A1, VDR, RXRα and RXRγ) vary between European, East-Asian and Sub-Saharan African-ancestry populations. Genes & Nutrition, 15(1), 1-11.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-NADSYN1 Recombinant Antibody (4G9)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare